As calsequestrin expression is restricted to skeletal muscle, patients with CASQ1 mutations show a mild form of TAM/STRMK with late-onset muscle weakness, myalgia, and abundant tubular aggregates, but without additional multi-systemic signs (Bohm and Laporte, 2018; Bohm et al., 2018). This evidence concerns the gene CASQ1 and Myalgia.